Logo image of ICVX

ICOSAVAX INC (ICVX) Stock Fundamental Analysis

NASDAQ:ICVX - Nasdaq - US45114M1099 - Common Stock - Currency: USD

15.31  -0.14 (-0.91%)

After market: 15.39 +0.08 (+0.52%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to ICVX. ICVX was compared to 559 industry peers in the Biotechnology industry. While ICVX has a great health rating, there are worries on its profitability. ICVX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ICVX had negative earnings in the past year.
In the past year ICVX has reported a negative cash flow from operations.
ICVX Yearly Net Income VS EBIT VS OCF VS FCFICVX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 -20M -40M -60M -80M

1.2 Ratios

ICVX has a better Return On Assets (-38.48%) than 62.67% of its industry peers.
Looking at the Return On Equity, with a value of -41.61%, ICVX is in the better half of the industry, outperforming 71.96% of the companies in the same industry.
Industry RankSector Rank
ROA -38.48%
ROE -41.61%
ROIC N/A
ROA(3y)-59.36%
ROA(5y)N/A
ROE(3y)-206.85%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ICVX Yearly ROA, ROE, ROICICVX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 -100 -200 -300 -400 -500

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ICVX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ICVX Yearly Profit, Operating, Gross MarginsICVX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 -5K -10K -15K

More info and screens

8

2. Health

2.1 Basic Checks

ICVX does not have a ROIC to compare to the WACC, probably because it is not profitable.
ICVX has more shares outstanding than it did 1 year ago.
There is no outstanding debt for ICVX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ICVX Yearly Shares OutstandingICVX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 10M 20M 30M 40M
ICVX Yearly Total Debt VS Total AssetsICVX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 50M 100M 150M 200M 250M

2.2 Solvency

ICVX has an Altman-Z score of 22.57. This indicates that ICVX is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of ICVX (22.57) is better than 92.74% of its industry peers.
There is no outstanding debt for ICVX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 22.57
ROIC/WACCN/A
WACC10.99%
ICVX Yearly LT Debt VS Equity VS FCFICVX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 0 100M 200M

2.3 Liquidity

A Current Ratio of 18.10 indicates that ICVX has no problem at all paying its short term obligations.
ICVX has a better Current ratio (18.10) than 91.55% of its industry peers.
A Quick Ratio of 18.10 indicates that ICVX has no problem at all paying its short term obligations.
ICVX has a Quick ratio of 18.10. This is amongst the best in the industry. ICVX outperforms 91.55% of its industry peers.
Industry RankSector Rank
Current Ratio 18.1
Quick Ratio 18.1
ICVX Yearly Current Assets VS Current LiabilitesICVX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 50M 100M 150M 200M 250M

More info and screens

3

3. Growth

3.1 Past

ICVX shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -1.83%.
The Revenue for ICVX has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)-1.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ICVX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.96% yearly.
ICVX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 194.45% yearly.
EPS Next Y5.52%
EPS Next 2Y3.44%
EPS Next 3Y-1.53%
EPS Next 5Y18.96%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y3.57%
Revenue Next 5Y194.45%

3.3 Evolution

ICVX Yearly Revenue VS EstimatesICVX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2025 2026 2027 2028 2029 2030 200M 400M 600M
ICVX Yearly EPS VS EstimatesICVX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ICVX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ICVX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ICVX Price Earnings VS Forward Price EarningsICVX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ICVX Per share dataICVX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.44%
EPS Next 3Y-1.53%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ICVX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ICOSAVAX INC

NASDAQ:ICVX (2/16/2024, 8:05:55 PM)

After market: 15.39 +0.08 (+0.52%)

15.31

-0.14 (-0.91%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2023-11-14/amc
Earnings (Next)N/A N/A
Inst Owners1.88%
Inst Owner Change-0.02%
Ins Owners14.46%
Ins Owner Change0%
Market Cap766.88M
Analysts78.33
Price Target18.87 (23.25%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.86%
Min EPS beat(2)3.68%
Max EPS beat(2)24.05%
EPS beat(4)4
Avg EPS beat(4)7.7%
Min EPS beat(4)1.1%
Max EPS beat(4)24.05%
EPS beat(8)5
Avg EPS beat(8)1.17%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)0
Avg Revenue beat(4)-100%
Min Revenue beat(4)-100%
Max Revenue beat(4)-100%
Revenue beat(8)1
Avg Revenue beat(8)-70.27%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-20.71%
EPS NQ rev (1m)0%
EPS NQ rev (3m)9.77%
EPS NY rev (1m)0%
EPS NY rev (3m)9.34%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.3
P/tB 3.3
EV/EBITDA N/A
EPS(TTM)-2.22
EYN/A
EPS(NY)-2.15
Fwd EYN/A
FCF(TTM)-1.47
FCFYN/A
OCF(TTM)-1.37
OCFYN/A
SpS0
BVpS4.64
TBVpS4.64
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -38.48%
ROE -41.61%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-59.36%
ROA(5y)N/A
ROE(3y)-206.85%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 179.55%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 18.1
Quick Ratio 18.1
Altman-Z 22.57
F-Score3
WACC10.99%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)643.03%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20%
EPS Next Y5.52%
EPS Next 2Y3.44%
EPS Next 3Y-1.53%
EPS Next 5Y18.96%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y3.57%
Revenue Next 5Y194.45%
EBIT growth 1Y-20.15%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-84.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-60.04%
OCF growth 3YN/A
OCF growth 5YN/A